Invited commentaryIn This Issue September 2017
References (21)
- et al.
Redox dysregulation, immuno-inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: pathophysiological and phenotypic implications
Schizophr. Res.
(2017) - et al.
The feasibility and clinical benefits of improving facial affect recognition impairments in schizophrenia: systematic review and meta-analysis
Schizophr. Res.
(2017) - et al.
A preliminary study of endocannabinoid system regulation in psychosis: distinct alterations in CNR1 promoter DNA methylation in patients with schizophrenia
Schizophr. Res.
(2017) Is there a viral or immune dysfunction etiology to schizophrenia? Re-evaluation a decade later
Schizophr. Res.
(1996)- et al.
Autism spectrum and psychosis isk in the 22q11.2 deletion syndrome. Findings from a prospective longitudinal study
Schizophr. Res.
(2017) - et al.
Completing the puzzle: the search for pieces in the understanding of psychosis risk in 22q11.2 deletion syndrome
Schizophr. Res.
(2017) - et al.
Negative subthreshold psychotic symptoms distinguish 22q11.2 deletion syndrome from other neurodevelopmental disorders: a two-site study
Schizophr. Res.
(2017) - et al.
Does integrated neurocognitive therapy (INT) reduce severe negative symptoms in schizophrenia outpatients?
Schizophr. Res.
(2017) - et al.
A controlled family study of cannabis users with and without psychosis
Schizophr. Res.
(2014) - et al.
Longitudinal trajectories of cortical thickness as a biological marker for psychosis in individuals with 22q11.2 deletion syndrome
Schizophr. Res.
(2017)
There are more references available in the full text version of this article.
Cited by (0)
Published by Elsevier B.V.